Amerigo Scientific is a leading provider specializing in providing high-quality antibody products for the biomedical and life science research communities. Utilizing our advanced platforms, we produce non-fucosylated antibody products with high purity and specificity. These antibodies are available in a variety of formats, designed as a valuable resource for scientists and researchers.
Fucosylation is a common post-translational modification of antibodies, whereby fucose sugar molecules are added to the N-linked glycans attached to the Fc region of antibodies. This modification plays a crucial role in the effector functions of antibodies by influencing their interaction with Fcγ receptors on immune cells. Non-fucosylated antibodies are antibodies with reduced or absent fucose sugar residues on their glycans. These antibodies have shown enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activities compared to their fucosylated counterparts, leading to improved therapeutic efficacy in cancer immunotherapy.
Fig.1 Non-fucosylated antibodies show enhanced antibody-ADCC.1
FUT8 is an enzyme that plays a key role in antibody fucosylation. FUT8 specifically catalyzes the transfer of a fucose residue to the core GlcNAc of N-linked glycans on antibodies. Conversely, inhibition of FUT8 or other fucosyltransferases can generate low or non-fucosylated antibodies. Therefore, using FUT8 knockout cells to produce antibodies lacking fucose residues is an approach to express non-fucosylated antibodies.
At Amerigo Scientific, we are excited to launch a cutting-edge antibody expression platform for the production of non-fucosylated antibodies by using FUT8-KO CHO cells. These cells have been engineered to knock out the FUT8 enzyme, leading to the production of non-fucosylated antibodies. Our experienced team of scientists utilizes state-of-the-art expression systems and purification techniques to produce high-quality non-fucosylated antibodies for a variety of applications, including therapeutic development and research. This innovative technology will be a valuable addition to our portfolio of antibody expression capabilities.
Fig.2 The fucosylation function of FUT8 enzyme.1
Non-fucosylated antibodies show several benefits, including improved antibody efficacy, reduced immunogenicity, and enhanced therapeutic potential. We offer a wide range of non-fucosylated antibody products targeting various antigens and molecules of interest. Our products are rigorously tested for quality and performance, ensuring reliable and reproducible results in your research.
Our non-fucosylated antibody products are specifically designed for research use only. These antibodies are engineered to have enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, making them ideal for applications such as in vitro and in vivo studies, flow cytometry, and immunohistochemistry. Moreover, we also offer tailored non-fucosylated antibody expression services. our dedicated team of experts is ready to assist you in the expression and production of high-quality non-fucosylated antibodies for your research and development needs.
Can't find a satisfied antibody? Please contact us to choose our non-fucosylated antibody products for your research needs and unlock the full potential of your experiments with enhanced sensitivity and specificity.
Reference
Browse Products by Target Initial
